Develops eye drugs for diseases like macular degeneration and glaucoma.
Jun 2026Revenue $276M/yrExpenses $278M/yr
No trend
Figures by year
When will Harrow be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $276M and expenses $278M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $272M | $242M | $30.5M |
| Dec 2024 | $200M | $191M | $8.82M |
| Dec 2023 | $130M | $130M | $431K |
| Dec 2022 | $88.6M | $86.7M | $1.92M |
| Dec 2021 | $72.5M | $70.9M | $1.61M |
| Dec 2020 | $48.9M | $48.5M | $385K |
| Dec 2019 | $51.2M | $56.0M | −$4.79M |
| Dec 2018 | $41.4M | $46.6M | −$5.22M |
| Dec 2017 | $26.8M | $38.9M | −$12.2M |
| Dec 2016 | $19.9M | $35.8M | −$15.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.